FDA Approves Adjuvant Alectinib for ALK+ Early-Stage NSCLC

The FDA has approved alectinib as adjuvant treatment in select patients with ALK-positive non–small cell lung cancer.

Related Keywords

Genentech Alecensa ,Levi Garraway ,Global Product Development At Genentech ,Genentech ,Global Product Development ,